Genta receives Nasdaq noncompliance notice
The company has until June 16, 2008 to regain compliance, which requires a closing bid price of the company’s common stock at or above $1 per share for
The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to Eli Lilly and Company’s (Lilly) olomorasib as a potential treatment for adults with advanced pancreatic cancer who have already received at least one prior systemic therapy.